Icon

UKONIQ (nda213176)- (EQ 200MG BASE)

UMBRALISIB TOSYLATE TG THERAPS
EQ 200MG BASE
No No
2035-May-26 2026-Feb-05
None None
None No
UKONIQ is a kinase inhibitor indicated for the treatment of adult patients with: • Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. • Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 200MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.